Green Cross Corporation operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Green Cross with three other
pharmaceutical manufacturers in Asia:
sales of 34.85 billion Indian Rupees [US$532.57 million]
of which 69%
(670.58 billion Korean Won [US$600.17 million]
of which 86%
was Bio Business Division), and
China Biologic Products, Inc.
based in China
(2.27 billion Chinese Renmimbi [US$329.80 million]
of which 100%
was Human Blood Product).
Green Cross reported sales of 1.20 trillion Korean Won (US$1.07 billion)
December of 2016.
increase of 14.3%
versus 2015, when the company's sales were 1.05 trillion Korean Won.
Sales at Green Cross have increased during each of the previous five years
(and since 2011, sales have increased a total of 56%).
Sales of Gcjbp saw an increase
that was more than double the company's growth rate: sales were up
365.4% in 2016, from
7.88 billion Korean Won to 36.65 billion Korean Won.
Green Cross also saw significant increases in sales in
Greencross Gclabcell (up 23.0% to 42.42 billion Korean Won)
Greencross Genome (up 103.1% to 5.14 billion Korean Won)
Not all segments of Green Cross experienced an increase in sales in 2016:
sales of Greencross Ms fell 3.5% to 86.16 billion Korean Won.